U.S. markets close in 1 hour 51 minutes
  • S&P 500

    4,124.88
    -16.71 (-0.40%)
     
  • Dow 30

    33,754.00
    +76.73 (+0.23%)
     
  • Nasdaq

    13,856.89
    -139.21 (-0.99%)
     
  • Russell 2000

    2,264.26
    +35.33 (+1.59%)
     
  • Crude Oil

    63.23
    +3.05 (+5.07%)
     
  • Gold

    1,735.30
    -12.30 (-0.70%)
     
  • Silver

    25.43
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1977
    +0.0023 (+0.19%)
     
  • 10-Yr Bond

    1.6430
    +0.0200 (+1.23%)
     
  • GBP/USD

    1.3780
    +0.0028 (+0.20%)
     
  • USD/JPY

    108.9540
    -0.0940 (-0.09%)
     
  • BTC-USD

    62,039.14
    -1,076.35 (-1.71%)
     
  • CMC Crypto 200

    1,338.25
    -37.53 (-2.73%)
     
  • FTSE 100

    6,939.58
    +49.09 (+0.71%)
     
  • Nikkei 225

    29,620.99
    +82.29 (+0.28%)
     

Titan Pharmaceuticals Moving Forward with its ProNeura™ Technology, Analysts Review

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Titan Pharmaceuticals , Inc. (TTNP), a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.

Probuphine, approved by the FDA in 2016, employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer.

Potential applications for ProNeura™, analysts review, and price target here READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/titan/

Probuphine an important therapeutic option to fight the growing opioid addiction pandemic.

On September 4th, the company announced the initiation of a pilot program in collaboration with the Nevada Center for Behavioral Health (NCBH) to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system.

Titan's product pipeline available in this comprehensive analyst report READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/titan/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source